Vitamin K2 as a potential therapeutic candidate for the prevention of muscle cramps in hemodialysis patients: A prospective multicenter, randomized, controlled, crossover pilot trial

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

How the Study Was Run

In design terms this was a randomized, placebo-controlled, crossover, multicenter and pilot study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Each person switched between Vitamin D, K2, Magnesium and Zinc and the comparison at some point, usually with a gap in between.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

This multicenter, randomized, placebo-controlled, crossover clinical trial was conducted from June 2019 to May 2020.

The primary endpoint was the frequency of muscle cramps during HD.

The secondary endpoints were severity and duration of muscle cramps during HD.

What Was Measured

The subject headings attached to it are Muscle Cramp, Pilot Projects, Renal Dialysis and Vitamin K 2.

Author keywords: Crossover trials, Hemodialysis, Safety and Vitamin K2.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Nutrition (Burbank, Los Angeles County, Calif.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.